Kümler, I. http://orcid.org/0000-0001-5082-3660
Sørensen, P. Grundtvig
Palshof, J.
Høgdall, E.
Skovrider-Ruminski, W.
Theile, S.
Fullerton, A.
Nielsen, P. G.
Jensen, B. Vittrup
Nielsen, D. L.
Funding for this research was provided by:
Oncoral Pharma
Innovationsfonden (5184-00055B)
Kræftens Bekæmpelse (R110-A7013)
Article History
Received: 20 July 2018
Accepted: 31 October 2018
First Online: 8 November 2018
Compliance with ethical standards
:
: The study was initiated by the primary investigator at the Department of Oncology, Herlev and Gentofte Hospital. All study medication was manufactured and provided by Oncoral Pharma ApS. The study was partly funded by grants from Innovationsfonden (Innovation Fund Denmark) and the Danish Cancer Society. Oncoral Pharma is partly owned by Peter G Nielsen and Ann Fullerton. All other authors declare no conflict of interests.
: All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.